Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 4/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | POLQ | O75417 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24784624 | 1.00 | CACNA1H (0.39) | CACNA1HGRIN1GRIN2BGRM5GRM2 | |
| SCHEMBL30103059 | 0.92 | KDM4E (0.40) | CACNA1HGRIN1GRIN2BGRM5GRM2 | |
| SCHEMBL30103113 | 0.90 | CACNA1H (0.38) | CACNA1HGRIN1GRIN2BTNIKPOLQ | |
| SCHEMBL24785835 | 0.90 | CACNA1H (0.38) | CACNA1HGRIN1GRIN2BTNIKPOLQ | |
| SCHEMBL30103044 | 0.86 | AXL (0.40) | GRM2PLA2G2AACLY | |
| SCHEMBL24785362 | 0.86 | AXL (0.40) | GRM2PLA2G2AACLY | |
| SCHEMBL24785079 | 0.86 | CACNA1H (0.40) | CACNA1HGRIN1GRIN2BPOLQ | |
| SCHEMBL30018338 | 0.86 | CACNA1H (0.40) | CACNA1HGRIN1GRIN2BPOLQ | |
| SCHEMBL30103022 | 0.84 | CACNA1H (0.41) | CACNA1HGRIN1GRIN2BGRM2TNIK | |
| SCHEMBL24785813 | 0.83 | GRIN2B (0.38) | CACNA1HGRIN2BGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115448913-A | Bicyclic compounds for the treatment of EP2, EP4 receptor mediated diseases | 武汉人福创新药物研发中心有限公司 | 2022-12-09 | — | — | CN | disclosed |